Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.67 |
| ▸ | CA2 | P00918 | 9/20 | 0.67 |
| ▸ | CA9 | Q16790 | 6/20 | 0.67 |
| ▸ | CA12 | O43570 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20389248 | 0.87 | CYP1A2 (0.61) | CA1CA2CA9CA12MAPT | |
| SCHEMBL1893008 | 0.86 | CYP1A2 (0.63) | MAPTKMT2AMEN1CYP1A2KDM4E | |
| SCHEMBL15899956 | 0.84 | CA1 (0.54) | CA1CA2CA9CA12MAPT | |
| SCHEMBL241662 | 0.84 | CA2 (0.67) | CA1CA2CA9CA12MAPT | |
| SCHEMBL28672560 | 0.84 | CA1 (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL8535425 | 0.83 | CA2 (0.65) | CA1CA2CA9CA12MAPT | |
| SCHEMBL8048626 | 0.83 | CYP1A2 (0.76) | MAPTKMT2AMEN1CYP1A2KDM4E | |
| SCHEMBL29673499 | 0.82 | CYP1A2 (0.58) | MAPTKMT2ACYP1A2KDM4EALDH1A1 | |
| SCHEMBL1395590 | 0.80 | CA1 (1.00) | CA1CA2CA9CA12MAPT | |
| SCHEMBL27747721 | 0.80 | CA1 (0.76) | CA1CA2CA9CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334298-B1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2025-08-07 | — | — | US | disclosed |
| US-12312341-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. | 2024-09-12 | — | — | US | disclosed |
| US-12084434-B2 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4334298-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11897871-B1 | Methods for treating cancer | SCORPION THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| WO-2022265993-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008006563-A1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
| US-5215570-A | Plant safening agents | CIBA-GEIGY CORPORATION (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0365484-B1 | SULFAMOYL PHENYL UREAS | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
| EP-0365484-A1 | Sulfamoyl phenyl ureas | CIBA-GEIGY AG (CH) | 1990-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300939-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | PIK3CA, PIK3CG, PIK3CD | CA1 3519/4885CA2 2860/4885CA9 2171/4885 |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | CA1 3444/4885CA2 1584/4885CA9 1242/4885 |
| US-11897871-B1 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | CA1 2709/4885CA2 1409/4885CA9 1355/4885 |
| US-12312341-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | CA1 2709/4885CA2 1409/4885CA9 1355/4885 |
| US-20240076289-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | CA1 2709/4885CA2 1409/4885CA9 1355/4885 |
| US-20250250259-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | CA1 2709/4885CA2 1409/4885CA9 1355/4885 |
| US-20240400543-A1 | METHODS FOR TREATING CANCER | PIK3CA, PTEN, BRCA1 | CA1 2709/4885CA2 1409/4885CA9 1355/4885 |
| US-12084434-B2 | Methods for treating cancer | PIK3CA, PTEN, BRCA1 | CA1 2709/4885CA2 1409/4885CA9 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.